Novo Nordisk(US:NVO) Yahoo Finance·2026-01-27 18:00Core Insights - Novo Nordisk experienced a significant decline in stock value, losing 40% in 2025 due to market share loss to competitors like Eli Lilly, with earnings dropping from $6.53 to $4.50 per share [1][6] - The beginning of 2026 saw a rebound in Novo Nordisk's stock, rising 22% year to date, suggesting a recovery in investor sentiment [2][6] - Demand for Novo Nordisk's oral Wegovy drug is strong, with 18,000 prescriptions in its second week, outperforming Eli Lilly's Zepbound, indicating potential for continued growth in the GLP-1 medication market [3][4] Company Performance - Novo Nordisk's earnings fell nearly 30% from Q1 to Q3 of 2025, reflecting the impact of competitive pressures [1] - The stock's price-to-earnings ratio is currently at 17, which may indicate undervaluation given the rising demand for its products [4] Market Dynamics - The strong initial demand for the oral version of Wegovy suggests a shift in consumer preference towards more convenient medication forms, potentially benefiting Novo Nordisk in the competitive landscape [3] - The stock's recovery in 2026 may be attributed to tax-loss harvesting by investors at the end of 2025, leading to renewed buying interest [2]